Policy / Regulatory

China Orders Whole‑Class Listing of "Orphine‑Type Substances" in Non‑Medicinal Narcotic and Psychotropic Catalogue – Tri‑Agency Control Takes Effect 1 October 2026
NHC (NHFPC)NMPA

China Orders Whole‑Class Listing of “Orphine‑Type Substances” in Non‑Medicinal Narcotic and Psychotropic Catalogue – Tri‑Agency Control Takes Effect 1 October 2026

China's Ministry of Public Security (MPS), the National Health Commission (NHC), and the National Medical Products Administration (NMPA) jointly issued an announcement deciding to list the entire class of "orphine‑type…

NMPA Releases 109th RLD Catalog for Chemical Generics – 30 New Product Specifications Added, 24 Supplemented

NMPA Releases 109th RLD Catalog for Chemical Generics – 30 New Product Specifications Added, 24 Supplemented

US Treasury Drafts China Pharma Investment Rules Likely to Preserve Licensing Deals – A Carve‑Out From Broader National‑Security Tightening

US Treasury Drafts China Pharma Investment Rules Likely to Preserve Licensing Deals – A Carve‑Out From Broader National‑Security Tightening

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
China's NHC Launches Pilot Plan to Expand Wholly Foreign-Owned Hospital Sector
NHC (NHFPC)NHSA (prev. SMIA)

China’s NHC Launches Pilot Plan to Expand Wholly Foreign-Owned Hospital Sector

NMPA Drafts Medical Representative Management Measures, Seeks Public Input
NMPA

NMPA Drafts Medical Representative Management Measures, Seeks Public Input

Chinese Pharmacopoeia Commission Approves Draft for ChP 2025 Edition
NMPA

Chinese Pharmacopoeia Commission Approves Draft for ChP 2025 Edition

National Reimbursement Drug List 2024 Expands Coverage with 91 New Drugs
NHSA (prev. SMIA)

National Reimbursement Drug List 2024 Expands Coverage with 91 New Drugs

Show More